结合多电解质:照亮神经退行性疾病检测和治疗的道路
Priyam Ghosh1, Parameswar Krishnan Iyer1,2,3
1Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India.
ACS applied materials & interfaces
|July 25, 2025
概括
结合多电解质 (CPE) 显示出对蛋白质错折疾病研究的希望. 它们的选择性结合和光特性有助于早期诊断和监测像阿尔茨海默氏症这样的神经退行性疾病.
科学领域:
- 生物材料科学 生物材料科学
- 神经科学是一个神经科学.
- 医疗成像医学成像
背景情况:
- 蛋白质错误折叠疾病 (PMDs) 是一个重大的健康问题.
- 目前对PMD的诊断和治疗策略存在局限性.
- 结合多电解质 (CPE) 正在成为PMD研究中的有前途的工具.
研究的目的:
- 审查CPE在蛋白质错折疾病研究中的作用和潜力.
- 突出CPE在诊断和监测PMD方面的能力.
- 探索CPE在神经退行性疾病中的治疗影响.
主要方法:
- 在PMD研究中对CPE现有文献的审查.
- 分析CPE的化学特性及其与疾病生物标志物的相互作用.
- 评估CPE在诊断成像和实时监测中的应用.
主要成果:
- CPE对疾病特异性生物标志物具有选择性结合,例如粉样β (Aβ) 聚合物.
- 在与Aβ聚合物相互作用时,CPE显示独特的光反应,使检测和监测成为可能.
- 对CPE的化学修饰提高了其诊断精度和多功能性.
结论:
- 对于PMD的早期,非侵入性诊断,CPE具有显著的潜力.
- 蛋白质聚合因子可以促进实时监测蛋白质聚合动力学.
- 对于CPE的多功能性使其成为神经退行性疾病诊断和治疗,特别是阿尔茨海默病的有价值的药物.
关键词:
聚合物 聚合物 聚合物阿尔茨海默氏症是阿尔茨海默氏症的疾病.粉样蛋白检测 粉样蛋白检测粉样蛋白成像成像 粉样蛋白成像结合的多电解质结合物在金属化过程中,神经保护是一种神经保护.蛋白质错误折叠疾病 蛋白质错误折叠疾病水溶性结合聚合物聚合物更多相关视频
10:04Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
Published on: October 20, 2017
13.6K
08:16Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
Published on: September 21, 2021
3.5K
相关概念视频
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710
Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Neural Regulation
40.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.1K
